Rituximab (IDEC-C2B8) Plus GM-CSF in Patients With Follicular B-Cell Lymphoma
Phase of Trial: Phase II
Latest Information Update: 13 Mar 2015
Price : $35 *
At a glance
- Drugs Rituximab (Primary) ; Sargramostim (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 21 Sep 2013 New source identified and integrated (M.D. Anderson Cancer Center; DM98-304).
- 20 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.